MX393360B - Composiciones y metodos para el tratamiento de la presbicia - Google Patents

Composiciones y metodos para el tratamiento de la presbicia

Info

Publication number
MX393360B
MX393360B MX2020002922A MX2020002922A MX393360B MX 393360 B MX393360 B MX 393360B MX 2020002922 A MX2020002922 A MX 2020002922A MX 2020002922 A MX2020002922 A MX 2020002922A MX 393360 B MX393360 B MX 393360B
Authority
MX
Mexico
Prior art keywords
presbyopia
treatment
methods
compositions
aceclidine
Prior art date
Application number
MX2020002922A
Other languages
English (en)
Other versions
MX2020002922A (es
Inventor
Gerald Horn
Lee Nordan
Original Assignee
Lenz Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lenz Therapeutics Inc filed Critical Lenz Therapeutics Inc
Publication of MX2020002922A publication Critical patent/MX2020002922A/es
Publication of MX393360B publication Critical patent/MX393360B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención provee composiciones y métodos para el tratamiento de la presbicia; las composiciones utilizan preferiblemente aceclidina separadamente o junto con un agente cicloplégico y/o con un agente tensoactivo no iónico e intensificador de viscosidad, o con concentraciones bajas de un agonista selectivo del receptor adrenérgico a-2.
MX2020002922A 2013-08-28 2014-08-22 Composiciones y metodos para el tratamiento de la presbicia MX393360B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361871215P 2013-08-28 2013-08-28
US201361882998P 2013-09-26 2013-09-26
US201361904510P 2013-11-15 2013-11-15
US201361917620P 2013-12-18 2013-12-18
US201461938438P 2014-02-11 2014-02-11
PCT/US2014/052256 WO2015031186A1 (en) 2013-08-28 2014-08-22 Compositions and methods for the treatment of presbyopia

Publications (2)

Publication Number Publication Date
MX2020002922A MX2020002922A (es) 2020-07-22
MX393360B true MX393360B (es) 2025-03-24

Family

ID=52584080

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002922A MX393360B (es) 2013-08-28 2014-08-22 Composiciones y metodos para el tratamiento de la presbicia
MX2016002623A MX2016002623A (es) 2013-08-28 2014-08-22 Composiciones y metodos para el tratamiento de la presbicia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016002623A MX2016002623A (es) 2013-08-28 2014-08-22 Composiciones y metodos para el tratamiento de la presbicia.

Country Status (22)

Country Link
US (1) US9089562B2 (es)
EP (3) EP3038610A4 (es)
JP (6) JP6426743B2 (es)
KR (4) KR102600484B1 (es)
CN (1) CN105792815B (es)
AU (2) AU2014311558B2 (es)
CA (1) CA2922802C (es)
DK (1) DK3542798T3 (es)
ES (1) ES3028364T3 (es)
FI (1) FI3542798T3 (es)
HK (1) HK1225654A1 (es)
HR (1) HRP20250507T1 (es)
HU (1) HUE071646T2 (es)
LT (1) LT3542798T (es)
MX (2) MX393360B (es)
PL (1) PL3542798T3 (es)
PT (1) PT3542798T (es)
RS (1) RS66821B1 (es)
SG (1) SG11201601412XA (es)
SI (1) SI3542798T1 (es)
SM (1) SMT202500311T1 (es)
WO (1) WO2015031186A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3049795A1 (en) 2011-09-20 2013-03-28 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
MX2016007902A (es) * 2013-12-18 2016-10-28 Gnt Llc Composiciones y metodos para el tratamiento del glaucoma.
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2016205071A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
AU2016280615B2 (en) * 2015-06-18 2020-10-01 Lenz Therapeutics Operations, Inc. Storage stable compositions and methods for the treatment of refractive errors of the eye
US12298602B2 (en) 2015-09-15 2025-05-13 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
CN110320676A (zh) * 2015-09-15 2019-10-11 星欧光学股份有限公司 隐形眼镜产品
US10845622B2 (en) 2015-09-15 2020-11-24 Largan Medical Co., Ltd. Multifocal contact lens and contact lens product
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
IT201700069664A1 (it) * 2017-06-22 2018-12-22 For Health Pharma S R L Nuova formulazione oftalmica a base di tropicamide
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
JP7274475B2 (ja) * 2017-07-20 2023-05-16 セインダ ファーマシューティカル グアンジョウ コーポレイション 近視の処置のための組成物および方法
WO2019112030A1 (ja) * 2017-12-08 2019-06-13 千寿製薬株式会社 水溶性高分子を含む水性液剤
HRP20220762T1 (hr) 2018-04-24 2022-09-16 Allergan, Inc. Upotreba pilokarpin-hidroklorida u liječenju prezbiopije
JP2021534217A (ja) * 2018-08-21 2021-12-09 アラーガン、インコーポレイテッドAllergan, Incorporated 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用
JP2020033290A (ja) * 2018-08-29 2020-03-05 興和株式会社 水性組成物
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
MX2021004183A (es) 2018-10-10 2021-10-26 Presbyopia Therapies Inc Composiciones y metodos para el tratamiento de la presbicia.
EP3980017A4 (en) * 2019-06-10 2023-06-28 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
AU2020290443A1 (en) * 2019-06-10 2022-02-03 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects
WO2021021646A1 (en) * 2019-07-26 2021-02-04 Allergan, Inc. Compositions and methods for treatment of presbyopia
US11273141B2 (en) 2020-05-18 2022-03-15 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
US20230190738A1 (en) * 2021-12-16 2023-06-22 Lenz Therapeutics, Inc. Compositions and methods for the treatment of eye conditions
IL305997A (en) * 2021-04-01 2023-11-01 Active Biotech Ab Laquinimod formulation for ocular use
US20220347170A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. Method of Reducing Brow Ache
KR102415950B1 (ko) 2021-07-13 2022-07-05 백두하 백국화 추출물, 모과 추출물 및 용안육 추출물의 혼합물을 유효성분으로 포함하는 눈 건강 기능 식품 및 이의 제조방법
WO2023086878A1 (en) 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
WO2023091439A1 (en) * 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
CN114588156B (zh) * 2022-04-22 2024-06-11 温州医科大学附属眼视光医院 一种眼用制剂及其在治疗老花眼中的应用
KR102678138B1 (ko) * 2022-09-29 2024-06-25 주식회사태준제약 브리모니딘을 포함하는 안과용 조성물
JP2025541565A (ja) * 2022-12-21 2025-12-19 デウン セラピューティックス インコーポレイテッド エナボグリフロジンを含む点眼剤の形態の医薬組成物
WO2024220441A1 (en) * 2023-04-17 2024-10-24 Lenz Therapeutics Operations, Inc. Methods for the treatment of presbyopia
AU2024322403A1 (en) * 2023-08-04 2026-02-12 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives
CN119700989A (zh) * 2023-09-28 2025-03-28 苏州普乐康医药科技有限公司 一种α-肾上腺素受体激动剂眼用组合物及其用途
US12414942B1 (en) * 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
US5073560A (en) * 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
AR034371A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
JP2003201241A (ja) 2001-10-22 2003-07-18 Rohto Pharmaceut Co Ltd 眼科用組成物
JP2004168709A (ja) * 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008537887A (ja) * 2005-04-15 2008-10-02 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ アスコルベート結合ペプチド
ES2329161T3 (es) 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
RU2009128703A (ru) * 2006-12-26 2011-02-10 Клт Плаг Диливери, Инк. (Us) Имплантаты, доставляющие лекарства, для уменьшения оптических дефектов
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010070664A1 (en) * 2008-11-17 2010-06-24 Laila Pharmaceuticals Pvt. Ltd. Curcuminoids and its metabolites for the application in ocular diseases
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
BRPI0924460A2 (pt) 2009-06-10 2018-03-27 Obschestvo S Ogranichennoi Otvetstvennostyu '"Mitorekh" composição farmacêutica para uso em oftalmologia médica e veterinária
US8614200B2 (en) * 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2796041A1 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
US20120225827A1 (en) * 2011-03-03 2012-09-06 Warner Kevin S Silicone-based ophthalmic formulations
CA3049795A1 (en) 2011-09-20 2013-03-28 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
CN105792815B (zh) 2018-08-28
PT3542798T (pt) 2025-05-20
DK3542798T3 (da) 2025-05-19
JP2016529297A (ja) 2016-09-23
KR20260008183A (ko) 2026-01-15
EP3542798A1 (en) 2019-09-25
KR20230157530A (ko) 2023-11-16
JP6426743B2 (ja) 2018-11-21
LT3542798T (lt) 2025-06-10
ES3028364T3 (en) 2025-06-19
JP2021183634A (ja) 2021-12-02
CA2922802C (en) 2021-04-27
AU2019200623B2 (en) 2019-10-03
KR20160045147A (ko) 2016-04-26
JP2020055851A (ja) 2020-04-09
JP2019031538A (ja) 2019-02-28
AU2014311558B2 (en) 2019-01-24
EP4563162A3 (en) 2025-08-20
CA2922802A1 (en) 2015-03-05
US9089562B2 (en) 2015-07-28
HK1225654A1 (zh) 2017-09-15
PL3542798T3 (pl) 2025-09-08
MX2016002623A (es) 2016-09-23
JP7329019B2 (ja) 2023-08-17
JP2023103400A (ja) 2023-07-26
EP4563162A2 (en) 2025-06-04
EP3542798B1 (en) 2025-03-19
EP3038610A4 (en) 2017-03-22
KR20220129097A (ko) 2022-09-22
JP2025131705A (ja) 2025-09-09
JP7358221B2 (ja) 2023-10-10
HRP20250507T1 (hr) 2025-06-20
SI3542798T1 (sl) 2025-07-31
EP3038610A1 (en) 2016-07-06
FI3542798T3 (fi) 2025-05-21
KR102905081B1 (ko) 2025-12-26
WO2015031186A1 (en) 2015-03-05
CN105792815A (zh) 2016-07-20
RS66821B1 (sr) 2025-06-30
MX2020002922A (es) 2020-07-22
AU2014311558A1 (en) 2016-03-17
SMT202500311T1 (it) 2025-09-12
SG11201601412XA (en) 2016-03-30
KR102600484B1 (ko) 2023-11-09
US20150065511A1 (en) 2015-03-05
AU2019200623A1 (en) 2019-02-21
HUE071646T2 (hu) 2025-09-28

Similar Documents

Publication Publication Date Title
MX393360B (es) Composiciones y metodos para el tratamiento de la presbicia
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2019014654A (es) Agonistas de fgfr1 y sus metodos de uso.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX373121B (es) Composiciones y metodos para el tratamiento de leucemia.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
BR112016018751A2 (pt) dispositivo de fornecimento de gás, estação de hidrogênio, e método de fornecimento de gás.
MX2017004896A (es) Uso de hexadeca-8, 15-dienal como producto quimico aromatico.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
PH12015502659A1 (en) Surface treatment compositions comprising photochromic dyes
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
NZ763528A (en) Heterocyclic gpr119 agonist compounds
WO2012142372A3 (en) Compositions and methods for the treatment of nasal conditions
MX2018011300A (es) Composiciones y metodos para el tratamiento de la presbicia.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
WO2014131024A3 (en) Guanylate cyclase receptor agonists for use in colonic cleansing
NZ626736A (en) Phragamalin limonoids for the treatment of sexual dysfunction
MX2016007902A (es) Composiciones y metodos para el tratamiento del glaucoma.
PH12017501864A1 (en) Compositions and methods for treating autism